McNeil Consumer Healthcare recalls all 100 count TYLENOL® Arthritis Pain Caplet bottles
McNeil Consumer Healthcare and the FDA are notifying consumers that McNeil is expanding its recent drug recall of TYLENOL Arthritis Pain Caplets to include all lots of 100 count bottles with the red EZ-OPEN CAP.
Last month, five lots of the product were recalled after consumers reported unusual moldy, musty, or mildew-like odors associated with nausea, stomach pain, vomiting and diarrhea. The odor is caused by the chemical 2,4,6-tribromoanisole, which is believed to be created through the breakdown of a chemical used to treat wooden pallets that were used for transporting and storing packaging materials.
There have been no reports of illness or injury related to these products; the company said it will discontinue the recalled 
The study, which was conducted on a total of 996 DME patients, revealed that people who took glitazone-containing drugs, like Avandia, were up to 2.6 times more likely to develop the disorder than those who were not taking the drugs. In fact, the risk of developing DME for glitazone users was up to 68% higher than for non-glitazone users. Avandia contains rosiglitazone, which belongs to the glitazone family.
FDA critics have long argued that the agency is overworked and simply unable to monitor the safety of the vast amounts of pharmaceutical drugs, medical products, and medical devices that come through its doors. The agency suffers from under staffing and a shortage of resources necessary to ensure drug safety. FDA officials, themselves, admit that the agency is unable to meet the changing demands of a globalized world, where pharmaceutical drugs are frequently sourced from foreign plants. In 2005, the FDA approved close to 3,200 applications for marketing of new medical devices. Yet, the agency has only a fraction of the scientist and researchers necessary to process so many applications. Because of this the FDA often has no other option, but to rely on the device makers themselves to disclose the risks of their products.
In recent years the FDA has battled several food safety crises. Every time there is a contaminated batch of peanut butter or pistachios, the agency is forced to turn its attention to food safety. It has become increasingly clear that we cannot continue to expect the agency, responsible for making sure tomatoes and peppers are free of pathogens, to also be responsible for monitoring the safety of .jpg)
Patients injured by the drugs are currently helpless in the face of the law. At the time the bill was passed, proponents insisted that it would attract pharmaceutical investment in the state; that theory has since been disproved. Pharmaceutical investments and companies have moved out of Michigan in recent years, taking valuable jobs with them..jpg)
Later that year, the .gif)
The allegations that Forest Laboratories Inc. concealed studies showing unfavorable results for Lexapro and Celexa seem to have received no attention by the FDA. On March 20th, the agency approved the use of Lexapro for use in adolescents. Lexapro is only the second antidepressant approved for use in younger patients.
Watson Pharmaceuticals Inc. says they are voluntarily recalling the lot of tablets to prevent any risk to patients due to over dosage. 
After being alerted by the .jpg)
Those who do survive may find themselves with severe neurological difficulties. People with AIDS who suffer from PML may find that the anti-HIV drugs they take can help alleviate the symptoms of PML. People taking medications that suppress immunity are especially at risk for PML. Of the 4 Raptiva users who contracted PML, no one was taking any other immune-suppressive medications. The FDA has confirmed that it will take steps to make sure that patients taking Raptiva are informed of PML symptoms and that these patients are monitored by healthcare professionals for any sign of the infection.
While it is very effective in the treatment of atrial flutter and other heart conditions, an overdose of Digoxin can have serious consequences on a person's health. Digoxin overdose can quickly lead to digitalis toxicity, whose symptoms include dizziness, blurred vision and other medical issues. In extreme cases, the victim can suffer from a decreased heart rate, pulse irregularities and palpitations. Digitalis toxicity can also impact the functioning of the kidneys. It is therefore an especially dangerous condition in patients who already suffer from kidney and renal disorders. Patients who took the double dose Digitek tablets were at risk of an overdose. The companies involved in producing the double dose tablets including Mylan Bertek Pharmaceuticals Inc, UDL Laboratories Inc., and Actavis Totowa have yet to provide solid explanations for why so many lots of these tablets contained twice the recommended dosage..jpg)
to pass it before Atlanta becomes the venue for the world's largest biotechnology conference in May. Earlier this year, Governor Perdue unveiled the legislation at a meeting of the Georgia Chamber of Commerce, outlining his intention of making it harder for victims to pursue civil liability claims against pharmaceutical companies. Basically, the bill grants immunity to drug and medical device manufacturers from any .gif)
